| scholarly article | Q13442814 |
| P50 | author | James Chih-Hsin Yang | Q37840097 |
| Denis Moro-Sibilot | Q57054866 | ||
| P2093 | author name string | Dong-Wan Kim | |
| Michael Duruisseaux | |||
| Ramaswamy Govindan | |||
| Mark A Socinski | |||
| Tommaso De Pas | |||
| D Ross Camidge | |||
| Leena Gandhi | |||
| Lucio Crino | |||
| Luigi De Petris | |||
| Shirish M Gadgeel | |||
| Alice T Shaw | |||
| Ji-Youn Han | |||
| Sai-Hong Ignatius Ou | |||
| Eric Dansin | |||
| Ali Zeaiter | |||
| Sophie Golding | |||
| Walter Bordogna | |||
| Alberto Chiappori | |||
| Antje Tessmer | |||
| P2860 | cites work | CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study | Q27852261 |
| Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. | Q27852806 | ||
| Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. | Q27853059 | ||
| First-line crizotinib versus chemotherapy in ALK-positive lung cancer | Q27853101 | ||
| Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial | Q27853299 | ||
| Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer | Q34449807 | ||
| Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib | Q35007620 | ||
| Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis | Q35057308 | ||
| Characteristics of long-term survivors of brain metastases from lung cancer | Q35078652 | ||
| Drug delivery to the central nervous system: a review | Q35205301 | ||
| Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases | Q35549714 | ||
| Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study | Q37606591 | ||
| Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies | Q38208748 | ||
| FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. | Q38371186 | ||
| Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. | Q38645064 | ||
| Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases | Q38957939 | ||
| Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2). | Q40548554 | ||
| Clinical characteristics of brain metastases from lung cancer according to histological type: Pretreatment evaluation and survival following whole-brain radiotherapy | Q41920066 | ||
| Irradiation of brain metastases from lung cancer: A retrospective study | Q45241708 | ||
| Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study | Q50711312 | ||
| CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. | Q54602410 | ||
| P433 | issue | 34 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lung cancer | Q47912 |
| P304 | page(s) | 4079-4085 | |
| P577 | publication date | 2016-10-31 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer | |
| P478 | volume | 34 |
| Q64984338 | (J)ALEX the great: a new era in the world of ALK inhibitors. |
| Q55262467 | ALK inhibitors, resistance development, clinical trials. |
| Q42359754 | ALK on my mind: alectinib takes an early lead in managing intracranial disease in non-small cell lung cancer with ALK rearrangements |
| Q42330754 | ASCEND-2: a canary in a coal mine for descending to second-line treatment for ALK-rearranged non-small cell lung cancer |
| Q39718035 | ASCENDing the anaplastic lymphoma kinase ladder: a tale of two C-nibs |
| Q89497162 | Advances in clinical trials of targeted therapy and immunotherapy of lung cancer in 2018 |
| Q92286653 | Adverse Events of Concurrent Radiotherapy and ALK Inhibitors for Brain Metastases of ALK-Rearranged Lung Adenocarcinoma |
| Q53707445 | Alectinib for advanced ALK-positive non-small-cell lung cancer |
| Q41820718 | Alectinib for the management of ALK-positive non-small cell lung cancer brain metastases |
| Q64122275 | Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases |
| Q58802261 | Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy |
| Q90646795 | Assessment of Effectiveness and Safety of Osimertinib for Patients With Intracranial Metastatic Disease: A Systematic Review and Meta-analysis |
| Q52318443 | Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment |
| Q91099817 | Brain metastases |
| Q55429658 | Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options? |
| Q64238209 | Brigatinib for -positive metastatic non-small-cell lung cancer: design, development and place in therapy |
| Q90731627 | Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer |
| Q89145785 | Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer |
| Q46080398 | Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC. |
| Q48109517 | Current chemotherapeutic regimens for brain metastases treatment |
| Q98771214 | Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and Low-Abundance EML4-ALK Variant in Liquid Biopsy: A Case Report |
| Q90566076 | Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib |
| Q90568504 | Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies |
| Q90356670 | Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS Metastases |
| Q90809080 | Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial |
| Q88497994 | Emerging Gene Fusion Drivers in Primary and Metastatic Central Nervous System Malignancies: A Review of Available Evidence for Systemic Targeted Therapies |
| Q50251062 | Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance |
| Q94366039 | Highlights from the Literature |
| Q38819349 | Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology |
| Q87597521 | Leptomeningeal Metastases |
| Q90947631 | Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? |
| Q45064344 | Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium |
| Q64326768 | New developments in brain metastases |
| Q92134597 | New generation anaplastic lymphoma kinase inhibitors |
| Q42318799 | New treatment options and challenges for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer with brain metastases |
| Q98612903 | Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors |
| Q39128273 | Optimizing treatment for patients with anaplastic lymphoma kinase-positive lung cancer |
| Q54116816 | Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience. |
| Q55710220 | Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer. |
| Q89870010 | Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer |
| Q38640845 | Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence |
| Q38688150 | Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer. |
| Q59341081 | Recent advances in managing brain metastasis |
| Q38748356 | Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer |
| Q42673256 | Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib |
| Q38663460 | Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy |
| Q57816905 | Strategies to Preserve Cognition in Patients With Brain Metastases: A Review |
| Q64238220 | Systematic review of sequencing of ALK inhibitors in -positive non-small-cell lung cancer |
| Q92255269 | Systemic therapy for brain metastases |
| Q39192200 | Targeted Treatment of Brain Metastases |
| Q47351169 | Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors |
| Q49956245 | Targeted therapy of brain metastases: latest evidence and clinical implications |
| Q64067749 | Targeting Molecular Pathways in Intracranial Metastatic Disease |
| Q37737536 | The Emerging Role of Targeted Therapy and Immunotherapy in the Management of Brain Metastases in Non-Small Cell Lung Cancer |
| Q52673453 | The Evolving Landscape of Brain Metastasis. |
| Q91709281 | The impact of systemic precision medicine and immunotherapy treatments on brain metastases |
| Q38906188 | Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP. |
| Q89493530 | Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies |
| Q90132769 | Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer |
| Q33832902 | Validation of the graded prognostic assessment for lung cancer with brain metastases using molecular markers (lung-molGPA). |
| Q47899183 | Whole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution? |
Search more.